| |
|
今井浩三 |
東京大学医科学研究所・特任教授 |
| 分子腫瘍学、臨床腫瘍学 |
| Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Nasuno M, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nakagaki S, Watanabe S, Idogawa M, Yamashita K, Naishiro Y, Adachi Y, Suzuki H, Fujimiya M, Imai K, Shinomura Y. Stem Cells 2014.32(4):913-925, doi: 10.1002/stem.1594. |
| Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y. Cancer Res. 2012; 72(5):1126-1136. |
| Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, Shinomura Y, Imai K, Toyota M. Cancer Res. 2011; 71: 5646-5658. |
|
| |
|
大津 敦 |
国立がん研究センター先端医療開発センター長 |
| 腫瘍内科 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Ohtsu A, et al, Lancet 376: 687-697, 2010 |
| TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Lancet Oncol. 13(10):993-1001, 2012 |
| Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). Ohtsu A, Shimada Y, Shirao K, et al. J Clin Oncol, 21: 54-59, 2003 |
|
| |
|
北島 政樹 |
国際医療福祉大学 学長 |
| 一般消化器外科、上部消化管、臓器移植、内視鏡外科（ロボット手術を含む） 、がんの臨床・ 基礎研究、医療機器開発 |
Surgical Treatment of Esophageal Cancer - The Advent of the Era of individualization .
Masaki Kitajima, Yuko Kitagawa
The New England Journal of Medicine,
November 2002,347(21),1705-1708
|
Langenbeck’s Archives-an international communication forum between Japanese and German surgeons
Masaki Kitajima,Yoshiki Hiki
Langenbecks Archives of Surgery,April 2010,395(1),57-67
|
Sentinel Nobe Mapping for Gastric Cancer :A Prospective Multicenter Trial in Japan
Y Kitagawa,H Takeuchi,Y Takagi,S Natsugoe,M Terashima,N Murakami,T Fujimuea,H Tsujimoto,H Hayashi,N Yoshimizu,A Takagane,Y Mohri,K Nabeshima,Y Uenosono,S Kinami,J Sakamoto,S Morita,T Aikou,K Miwa and M Kitajima
JOURNAL of Clinical ONCOLOGY,Sep2013,31(29),3704-3710
|
|
| ○ |
|
高橋 利忠 |
愛知県がんセンター・名誉総長、
健康科学総合センター・名誉センター長
|
| 腫瘍免疫学 |
Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen.
Tsujimura, K., Obata, Y., Takahashi, T.
Cancer Sci.2004; 95: 469-474.
|
Kawase,T.,Akatsuka,Y.,Torikai,H.,Morishima,S.,Oka,A.,Tsujimura,A.,
Miyazaki,M.,Tsujumura,K.,Miyamura,K.,Ogawa,S.,Inoko,H.,
Morishima,Y., Kodera,y., Kuzushima,K.., Takahashi,T.
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.
Blood. 2007; 110: 1055-1063.
|
A Minor histocompatibility antigen as targets for immunotherapy utilizing allogeneic immune reactions.
Akatuka, Y., Morishima, Y., Kuzushima, K., Kodera, Y., Takahashi, T
Cancer Sci. 2009;78:1139-1146
|
|
| |
|
中西 洋一 |
九州大学大学院・教授 |
| 呼吸器内科学、肺腫瘍学、臨床試験 |
| Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale R, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F. J Clin Invest, 1988, 82: 354-359 |
| Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. Nakanishi Y, Pei X-H, Takayama K, Bai F, Izumi M, Kimotsuki K, Inoue K, Minami T, Wataya H, Hara H. Am J Respir Cell Mol Biol, 2000, 22:747-754 |
EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Harada C, Kawaguchi T, Ogata-Suetsugu S, Yamada M, Hamada N, Maeyama T, Souzaki R,
Tajiri T, Taguchi T, Kuwano K, Nakanishi Y. Am J Respir Crit Care Med. 2011, 183:743-51
|
|
| |
|
野田 哲生 |
公益財団法人がん研究会
代表理事・常務理事 がん研究所 所長
|
| 分子遺伝学 |
| H. Takeshima, M. Iino, H. Takekura, M. Nishi, J. Kuno, O. Minowa, H. Takano and T. Noda. (1994) Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature, 369: 556-559. |
| H. Shibata, K. Toyama, H. Shioya, M. Ito, M. Hirota, S. Hasegawa, H. Matsumoto, H. Takano, T. Akiyama, K. Toyoshima, R. Kanamaru, Y. Kanegae, I. Saito, Y. Nakamura, K. Shiba and T. Noda. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science, 278: 120-123. |
| R. Yao, Y. Kondoh, Y. Natsume, H. Yamanaka, M. Inoue, H. Toki, R. Takagi, T. Shimizu, T. Yamori, H. Osada and T. Noda. (2014) A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene, 33: 4242-4252. |
|
| |
|
福岡 正博 |
和泉市立病院 総長 |
| がん化学療法、肺がんの治療、がんトランスレーショナルリサーチ |
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Fukuoka M, Yano S, et al., J Clin Oncol. 21: 2237-2246, 2003. |
| Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ohe Y, Fukuoka M, et al., Ann Oncol. 18: 317-323, 2007 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Mok TS, et al., J Clin Oncol. 29: 2866-2874, 2011. |
|
| |
|
門田 守人 |
がん研有明病院・病院長 |
| 消化器外科 |
| Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Ritchie SA1, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, et al. BMC Cancer. 2013 Sep 12;13:416. |
| 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. Hepatol Res. 2012 Feb;42(2):150-65. |
| Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan. Br J Surg. 2011 Apr;98(4):552-7. |
|
